|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Combretastatin A -4, an agent that displays potent and selective toxicity toward tumor vasculature显示文摘 | Dark GG Hil SA Prise VE | 1997 | Cancer Res1997，57，： | 1 |
| 2 | Combretastatin A-4,an agent that displays potent and selective toxicity toward tumor vasculature显示文摘 | Dark GG Hill SA Prise VE | 1997 | Cancer Res1997，57，10： | 1 |
| 3 | Combretastatin A -4, an agent that displays potent and selective toxicity toward tumor vasculature 显示文摘 | Dark GG Hill SA Prise VE | 1997 | Cancer Res1997，57，： | 1 |
| 4 | Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non- small cell lung cancer:a multicenter,randomized,phase Ⅱ trial显示文摘 | Scagliotti GV Kortsik C Dark GG | 2005 | Clin Cancer Res2005，11，21： | 1 |
| 5 | Pemetrexed combined with oxalip latin or carbop latin as first2line treatment in advanced non-small cell lung cancer:a multicenter,randomized Phase Ⅱ trail显示文摘 | Scagliotti G Kortsik C Dark GG | 2005 | Clin Cancer Res2005，11，21： | 1 |
| 6 | Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, phase Ⅱ trial 显示文摘 | Scagliotti GV Kortsik C Dark GG | 2005 | Clin Cancer Res2005，11，21： | 1 |
| 7 | Combretastatin A-4,an agent that displays potent and selective toxicity toward tumor vasculature显示文摘 | DARK GG HILL SA PRISE VE | 1997 | Cancer Res1997，57，10： | 1 |
| 8 | Pemetrexed combined with ox- aliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer:a multicenter,randomized,phase 1I triM显示文摘 | Scagliotti GV Kortsik C Dark GG | 2005 | Clin Cancer Res2005，11，2： | 1 |
| 9 | Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, phase Ⅱ tri- al显示文摘 | Scagliotti GV Kortsik C Dark GG | 2005 | Clin Cancer Res2005，11，21： | 1 |
| 10 | Differentiation and definition of vascular-targeted therapies 显示文摘 | Siemann DW Bibby MC Dark GG | 2005 | Clin Cancer Res2005，11，21： | 1 |
| 11 | Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized,phase 1/ trial显示文摘 | Scagliotti GV Kortsik C Dark GG | 2005 | Clin Cancer Res2005，11，21： | 1 |
| 12 | Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature显示文摘 | DARK GG HILL SA PRISE VE | 1997 | CancerRes1997，57，10： | 1 |
| 13 | Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, phase II trim 显示文摘 | Scagliotti GV Kortsik C Dark GG | 2005 | Clin Cancer Res2005，11，21： | 1 |
| 14 | Pemetrexed combined with oxaliplatin or carboplatin as first-linetreatment in advanced non-small cell lung cancer: amuhicenter, randomized, phase Ⅱ trial显示文摘 | Scagliotti GV Kortsik C Dark GG | 2005 | Clin Cancer Res2005，11，： | 1 |
| 15 | Combretastatin A -4, an agent that displays potent and selective toxicity toward tumor vasculature显示文摘 | Dark GG Hill SA Prise VE | 1997 | Cancer Res1997，57，： | 1 |
| 16 | Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, phase II trial 显示文摘 | Scagliotti GV Kortsik C Dark GG | 2005 | Grin Cancer Res2005，11，21： | 1 |
| 17 | Pemetrexed combined with oxaliplatin or carboplatin as first line treatment in advanced non small cell lung cancer: a muhicenter, randomized, phase Ⅱ trial显示文摘 | Scagliotti GV Kortsik C Dark GG | 2005 | Clin Cancer Res2005，11，21： | 1 |
| 18 | Pemetrexed combined with oxaliplatin or carboplatin asfirst-line treatment in advanced nonsmall cell lung cancer:a multicenter,randomized,phase Ⅱ trial显示文摘 | Scagliotti GV Kortsik C Dark GG | | 0，，2： | 1 |
| 19 | Combretastatin A-4,an agent that displays potent and selective toxicity toward tumor vasculature显示文摘 | Dark GG Hill SA Prise VE | 1997 | Cancer Res1997，57，10： | 1 |
| 20 | Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in ad- vanced non-small cell lung cancer: a multicenter, randomized, phase II trial 显示文摘 | Scagliotti GV Iortsik C Dark GG | 2009 | Clinical cancer research2009，11，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员